Search

Your search keyword '"Del Prato, S."' showing total 1,283 results

Search Constraints

Start Over You searched for: Author "Del Prato, S." Remove constraint Author: "Del Prato, S."
1,283 results on '"Del Prato, S."'

Search Results

151. Subcutaneous insulin infusion (CSII) in italy: The third national survey

152. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes

154. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial

156. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction

157. Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance

158. Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy

160. Il rischio residuo nelle dislipidemie: ruolo delle lipoproteine ad alta densità e dei trigliceridi plasmatici

162. Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database

163. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patient with primary hypercholesterolemia: results from the ECLIPSE study

164. In situ Protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy

165. Correspondence between the International Diabetes Federation criteria for metabolic syndrome and insulin resistance in a cohort of Italian nondiabetic Caucasians: the GISIR database

166. Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database

167. Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients

175. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

182. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum

185. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria

187. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) (vol 33, pg 1635, 2012)

189. Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance

190. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

191. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation

192. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

193. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

195. Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study

197. La terapia insulinica nel diabete mellito tipo 2

199. Diabete ­e ­cancro

Catalog

Books, media, physical & digital resources